

**PROLEUKIN- aldesleukin injection, powder, lyophilized, for solution**  
**Clinigen Limited**

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use PROLEUKIN® safely and effectively. See full prescribing information for PROLEUKIN.

**PROLEUKIN (aldesleukin) for injection, for intravenous use**

Initial U.S. Approval: 1992

**WARNING: CAPILLARY LEAK SYNDROME (CLS), NEUROLOGIC TOXICITY, AND SERIOUS INFECTIONS**

*See full prescribing information for complete boxed warning.*

- Capillary Leak Syndrome (CLS) including life-threatening or fatal reactions, has occurred in patients treated with Proleukin. Administer Proleukin in a hospital setting with an intensive care unit. Withhold or discontinue Proleukin as recommended. (2.4, 4, 5.1)
- Neurologic toxicities, which may be life-threatening or result in coma or permanent neurological deficits, have occurred in patients treated with Proleukin. Withhold or discontinue Proleukin as recommended. (2.4, 5.2)
- Serious infections including sepsis and bacterial endocarditis have occurred in patients treated with Proleukin. Treat preexisting bacterial infections prior to initiating Proleukin and withhold Proleukin as recommended. (2.4, 5.3)

**INDICATIONS AND USAGE**

Proleukin is a lymphocyte growth factor indicated for:

- The treatment of adults with metastatic renal cell carcinoma. (1.1)
- The treatment of adults with metastatic melanoma. (1.2)

**DOSAGE AND ADMINISTRATION**

Administer Proleukin in an inpatient hospital setting with an intensive care facility.

- Evaluate cardiovascular, pulmonary, neurologic and renal function before beginning Proleukin. (2.1)
- See Full Prescribing Information for Premedication and Supportive Medications. (2.3)
- Recommended dosage: 600,000 IU/kg (0.037 mg/kg) every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Following 9 days of rest, repeat the schedule for a maximum of another 14 doses (total of 28 doses per course, as tolerated). (2.2)
- Evaluate patients approximately 4 weeks after completion of a course of therapy and again immediately prior to the start of the next course. (2.2)
- Dose modification for toxicity should be accomplished by withholding or interrupting a dose. (2.4)
- Follow reconstitution and dilution procedures. (2.5)

**DOSAGE FORMS AND STRENGTHS**

For Injection: 22 million International Units (1.3 mg) lyophilized powder in a single-dose vial. (3)

**CONTRAINDICATIONS**

- Hypersensitivity to aldesleukin. (4)
- Organ allografts. (4)
- Significant organ impairment. (4)

**WARNINGS AND PRECAUTIONS**

- **Renal Toxicity:** Monitor renal function at baseline and throughout treatment. Withhold Proleukin or permanently discontinue, based on severity. (2.4, 5.4)
- **Immune-mediated Adverse Reactions:** Exacerbation of pre-existing autoimmune disease or initial presentation of autoimmune and inflammatory disorders can occur in any system or tissue. Proleukin may increase the risk of allograft rejection in transplant patients. Monitor patients and treat as indicated. (5.5)
- **Severe Hypersensitivity Reaction:** Permanently discontinue Proleukin for severe hypersensitivity reactions. (4, 5.9)
- **Embryo-Fetal Toxicity:** May cause fetal harm. Advise females of reproductive potential of potential risk to a fetus and to use effective contraception. (5.6, 8.1, 8.3)

**ADVERSE REACTIONS**

Most common ( $\geq 30\%$ ) adverse reactions including laboratory abnormalities are hypotension, hyperbilirubinemia, dyspnea, rash, diarrhea, oliguria, chills, vomiting, thrombocytopenia, nausea, confusional state and increased creatinine. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Clinigen, Inc. at 1-877-776-5385 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**DRUG INTERACTIONS**

See Full Prescribing Information for important drug interactions. (7)

**USE IN SPECIFIC POPULATIONS**

- Pregnancy: May cause fetal harm. (8.1)
- Lactation: Advise not to breastfeed. (8.2)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 9/2023**

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**WARNING: CAPILLARY LEAK SYNDROME (CLS), NEUROLOGIC TOXICITIES and**

**SERIOUS INFECTIONS****1 INDICATIONS AND USAGE**

- 1.1 Metastatic Renal Cell Carcinoma
- 1.2 Metastatic Melanoma

**2 DOSAGE AND ADMINISTRATION**

- 2.1 Recommended Evaluation and Testing Before Initiating Proleukin
- 2.2 Recommended Dosage
- 2.3 Premedication and Supportive Medications
- 2.4 Dosage Modifications for Adverse Reactions
- 2.5 Preparation and Administration

**3 DOSAGE FORMS AND STRENGTHS****4 CONTRAINDICATIONS****5 WARNINGS AND PRECAUTIONS**

- 5.1 Capillary Leak Syndrome
- 5.2 Neurologic Toxicity
- 5.3 Serious Infections Including Sepsis
- 5.4 Renal Toxicity
- 5.5 Immune-mediated Adverse Reactions
- 5.6 Embryo-Fetal Toxicity
- 5.7 Serious Manifestations of Eosinophilia
- 5.8 Delayed Adverse Reactions to Iodinated Contrast Media
- 5.9 Severe Hypersensitivity Reactions
- 5.10 Infusion-Related Reactions

**6 ADVERSE REACTIONS**

- 6.1 Clinical Trials Experience
- 6.2 Post Marketing Experience

**7 DRUG INTERACTIONS**

- 7.1 Effect of Other Drugs on Proleukin
- 7.2 Effect of Proleukin on Other Drugs

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

**10 OVERDOSAGE****11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 12.6 Immunogenicity

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

**14 CLINICAL STUDIES**

- 14.1 Metastatic Renal Cell Cancer
- 14.2 Metastatic Melanoma

**16 HOW SUPPLIED/STORAGE AND HANDLING****17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

**FULL PRESCRIBING INFORMATION**

**WARNING: CAPILLARY LEAK SYNDROME (CLS), NEUROLOGIC TOXICITIES and SERIOUS INFECTIONS**

- Capillary leak syndrome (CLS), including life threatening or fatal reactions, has occurred in patients treated with Proleukin. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, and hepatic impairment. Administer Proleukin in a hospital setting with an intensive care facility. Withhold or discontinue Proleukin as recommended [see *Dosage and Administration* (2.4), *Contraindications* (4), *Warnings and Precautions* (5.1)].
- Neurologic toxicities, which may be life-threatening or result in coma or permanent neurological deficits, have occurred in patients treated with Proleukin. Withhold or discontinue Proleukin as recommended [see *Dosage and Administration* (2.4), *Warnings and Precautions* (5.2)].
- Serious Infections including sepsis and bacterial endocarditis have occurred in patients treated with Proleukin. Treat pre-existing bacterial infections prior to initiation of Proleukin therapy and withhold Proleukin as recommended [see *Dosage and Administration* (2.4), *Warnings and Precautions* (5.3)].

## **1 INDICATIONS AND USAGE**

### **1.1 Metastatic Renal Cell Carcinoma**

Proleukin is indicated for the treatment of adults with metastatic renal cell carcinoma (RCC).

### **1.2 Metastatic Melanoma**

Proleukin is indicated for the treatment of adults with metastatic melanoma.

## **2 DOSAGE AND ADMINISTRATION**

### **2.1 Recommended Evaluation and Testing Before Initiating Proleukin**

Conduct baseline hematologic, chemistry, renal and hepatic function tests. Additionally, evaluate cardiac ejection fraction, coronary artery disease as appropriate, pulmonary function with PFTs, and evaluate for renal, hepatic, and CNS impairment prior to initiating treatment with Proleukin [see *Contraindications* (4), *Warnings and Precautions* (5.1, 5.2)].

Verify pregnancy status of females of reproductive potential prior to initiating Proleukin [see *Warnings and Precautions* (5.6), *Use in Specific Populations* (8.1, 8.3)].

### **2.2 Recommended Dosage**

Administer Proleukin in an inpatient hospital setting. An intensive care facility with specialists skilled in cardiopulmonary or intensive care medicine must be available [see *Warnings and Precautions* (5.1)].

The recommended dosage of Proleukin for metastatic renal cell carcinoma and metastatic melanoma is described in Table 1.

Administer Proleukin as an intravenous infusion after dilution [see *Dosage and Administration* (2.5)].

Administer pre-infusion medications and supportive treatment, as appropriate, prior to and during each infusion [see *Dosage and Administration* (2.3)]. Discontinue Proleukin for unacceptable toxicity [see *Dosage and Administration* (2.4)].

**Table 1: Recommended Dosage of Proleukin**

Each course of therapy consists of the following:		
Cycle 1	Days 1-5	600,000 IU/kg (0.037 mg/kg) every 8 hours; maximum of 14 doses <sup>1</sup>
Rest period	Days 6-14	
Cycle 2	Days 15-19	600,000 IU/kg (0.037 mg/kg) every 8 hours; maximum of 14 doses <sup>1</sup>

<sup>1</sup> A maximum of 28 doses (2 cycles) per treatment course

Evaluate patients for response approximately 4 weeks after completion of a course of

therapy and again immediately prior to the scheduled start of the next treatment course.

Additional courses of treatment may be administered to patients if there is a treatment response following the last course, and the patient did not experience any adverse reactions in previous course(s) that led to permanent discontinuation [see *Dosage and Administration* (2.4)].

Separate each treatment course by a rest period of at least 7 weeks from the date of hospital discharge.

### **2.3 Premedication and Supportive Medications**

Premedicate patients with an antipyretic immediately prior to beginning Proleukin. Continue antipyretics during treatment as needed for fever [see *Warnings and Precautions* (5.1, 5.10)].

Administer prophylactic antibiotics per institutional guidelines prior to beginning Proleukin and throughout the treatment course for patients with indwelling central catheters [see *Warnings and Precautions* (5.3)].

Administer prophylactic medication for gastrointestinal irritation and bleeding during each Proleukin treatment course [see *Adverse Reactions* (6.1)].

Additional medications may be needed if patients experience hypotension, dyspnea, rigors, nausea, diarrhea, pruritis, or dermatitis [see *Warnings and Precautions* (5.1, 5.8, 5.9)].

### **2.4 Dosage Modifications for Adverse Reactions**

No dose reduction for Proleukin is recommended for adverse reactions. In general, withhold or interrupt a dose or permanently discontinue Proleukin based on the severity of the adverse reaction as described in Table 2.

**Table 2: Recommended Dosage Modifications for Adverse Reactions**

Adverse Reaction	Severity	Dosage Modification
Cardiovascular [see <i>Warnings and Precautions</i> (5.1)]	<ul style="list-style-type: none"><li>• Atrial fibrillation,</li><li>• Supraventricular tachycardia, or</li><li>• Bradycardia that requires treatment or is recurrent or persistent</li><li>• Decrease in systolic blood pressure to &lt;90 mmHg</li></ul>	Withhold until patient is asymptomatic with full recovery to normal sinus rhythm
	<ul style="list-style-type: none"><li>• Sustained ventricular tachycardia (<math>\geq 5</math> beats)</li><li>• Cardiac rhythm disturbances not controlled or unresponsive to management</li><li>• ECG changes consistent with ischemia or myocardial infarction or angina/chest pain</li><li>• Cardiac tamponade</li></ul>	Permanently discontinue
Respiratory [see <i>Warnings and Precautions</i> (5.1)]	<ul style="list-style-type: none"><li>• O<sub>2</sub> saturation &lt;90%</li></ul>	Withhold until O <sub>2</sub> saturation is >90%
	<ul style="list-style-type: none"><li>• Intubation for &gt;72 hours</li></ul>	Permanently discontinue
Neurologic [see <i>Warnings and Precautions</i> (5.2)]	<ul style="list-style-type: none"><li>• Mental status changes, including moderate confusion or agitation</li></ul>	Withhold until completely resolved
	<ul style="list-style-type: none"><li>• Coma or toxic psychosis lasting &gt;48 hours</li><li>• Repetitive or difficult to control seizures</li></ul>	Permanently discontinue
Gastrointestinal [see <i>Warnings and Precautions</i> (5.1)]	Fecal immunochemical test (FIT) or fecal occult blood test (FOBT) positive	Withhold until FIT or FOBT negative
	Bowel ischemia/perforation or GI bleeding requiring surgery	Permanently discontinue
Hepatic [see <i>Warnings and Precautions</i> (5.1)]	Signs of hepatic toxicity including liver pain or $\geq$ Grade 3 AST or ALT elevation	Withhold all further treatment for that course. Initiate a new course of treatment no sooner than 7 weeks after signs of hepatic toxicity have resolved and hospital discharge
	Hepatic failure	Permanently discontinue
Dermatologic [see <i>Warnings and Precautions</i> (5.5, 5.7)]	Bullous dermatitis or marked worsening of pre-existing skin condition	Withhold until all signs of bullous dermatitis have resolved
Infectious	Sepsis syndrome, patient is clinically unstable	Withhold until sepsis syndrome has resolved,

[see Warnings and Precautions (5.3)]		patient is clinically stable, infection is under treatment
Renal [see Warnings and Precautions (5.1, 5.4)]	Serum creatinine >4.5 mg/dL or a serum creatinine of ≥4 mg/dL in the presence of severe volume overload, acidosis, or hyperkalemia	Withhold until serum creatinine levels return to normal (<1.5 mg/dL) or baseline and fluid and electrolyte status are stable
	Persistent oliguria, urine output of <10 mL/hr for 16-24 hours with rising SCr	Withhold until urine output >10 mL/hour with a decrease of serum creatinine >1.5 mg/dL or normalization of serum creatinine
	Renal failure requiring dialysis >72 hours	Permanently discontinue

## 2.5 Preparation and Administration

### Preparation

Reconstitute Proleukin using Sterile Water for Injection, USP. Do not reconstitute or dilute Proleukin with Bacteriostatic Water for Injection, or 0.9% Sodium Chloride Injection.

- Add 1.2 mL of Sterile Water for Injection, USP, by injecting the water along the walls of the vial and not directly on the lyophilized powder. The resulting concentration is 18 million IU (1.1 mg)/mL of Proleukin.
- The prepared solution is a clear, colorless to slightly yellow liquid.
- Slowly swirl the vial; do not shake.
- Withdraw the required dose of Proleukin and discard the vial with any unused portion.
- Use polyvinyl chloride bags for dilution of Proleukin and dilute using 5% Dextrose Injection to a concentration between 0.03 mg/mL and 0.07 mg/mL based on the required dose as follows:

**Table 3: Recommended Proleukin Dilution**

Dose	5% Dextrose Volume
≤25.4 million IU (≤1.5 mg)	25 mL
>25.4 million IU-60 million IU (>1.5 mg-3.5 mg)	50 mL
>60 million IU (>3.5 mg)	100 mL

### Storage of Diluted Proleukin Infusion Solution

- Store under refrigeration at 2° to 8°C (36° to 46°F) for no more than 48 hours from the time of preparation to the end of the infusion.
- Protect from light.
- Do not freeze.
- Allow the diluted solution to come to room temperature prior to administration.

### Administration

- **Do not use in-line filters when administering Proleukin.**
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- Do not co-administer Proleukin with other drugs through the same intravenous line.
- Administer by intravenous infusion over 15 minutes.

## 3 DOSAGE FORMS AND STRENGTHS

For Injection: 22 million International Units (1.3 mg) of aldesleukin available as a white to off-white, lyophilized powder in a single-dose vial for reconstitution. When reconstituted, each mL contains 18 million International Units (1.1 mg) aldesleukin.

## 4 CONTRAINDICATIONS

- **Severe Hypersensitivity Reactions**

Proleukin is contraindicated in patients with a known history of severe hypersensitivity to aldesleukin or any component of the Proleukin formulation [see Adverse Reactions (6.2)].

- **Organ Allografts**

Proleukin is contraindicated in patients with organ allografts [see Warnings and Precautions (5.5)].

- **Significant Organ Impairment**

Proleukin is contraindicated in patients with significant cardiac (including those with an abnormal cardiac ejection fraction, impaired wall motion, or significant coronary artery disease), pulmonary (including those with an FEV1 ≤ 2 liters or < 75% predicted for

height and age), renal, hepatic, or CNS impairment [see *Warnings and Precautions* (5.1, 5.2, 5.4)].

## 5 WARNINGS AND PRECAUTIONS

### 5.1 Capillary Leak Syndrome

Severe and life-threatening capillary leak syndrome (CLS) characterized by hypotension, dyspnea, edema, and hypoalbuminemia can occur with Proleukin, and can result in end organ toxicity including cardiac, respiratory, renal, hepatic toxicity, or death. Do not administer Proleukin to patients with significant cardiac, pulmonary, renal, or hepatic impairment. Avoid concomitant use of Proleukin with other products known to cause hypotension including antihypertensive drugs, those that cause renal toxicity, or hepatotoxicity.

CLS may begin immediately after Proleukin treatment is initiated. Monitor for signs and symptoms of CLS including assessments of vital signs, weight, fluid intake, albumin levels and urine output.

Withhold or discontinue Proleukin for failure to maintain organ perfusion as demonstrated by altered mental status, reduced urine output, oxygen saturation <90%, a fall in the systolic blood pressure below 90 mm Hg, or onset of cardiac arrhythmias. Initiate standard management for CLS, which may include intensive care [see *Dosage and Administration* (2.4), *Use in Specific Populations* (8.1)].

### 5.2 Neurologic Toxicity

Proleukin can cause neurologic toxicities including mental status changes, speech difficulties, cortical blindness, limb or gait ataxia, hallucinations, agitation, obtundation, demyelinating polyneuropathy, and coma. Alterations in mental status may progress for several days before recovery begins. Permanent neurologic deficits have occurred. Radiological findings included multiple and, less commonly, single cortical lesions on MRI and evidence of demyelination. One case of possible cerebral vasculitis has been reported.

Monitor patients for signs and symptoms of neurological toxicity during Proleukin treatment. Withhold Proleukin in patients developing moderate to severe lethargy or somnolence; continued administration may result in coma. Permanently discontinue Proleukin for coma or toxic psychosis lasting >48 hours or for repetitive or difficult to control seizures [see *Dosage and Administration* (2.4)].

Evaluate and treat CNS metastases prior to initiation of Proleukin. If possible, avoid concomitant use of Proleukin with other product(s) with a known potential to cause neurotoxicity, and avoid Proleukin in patients with seizure disorders or abnormal intracranial imaging [see *Contraindications* (4), *Adverse Reactions* (6.1, 6.2)].

Concomitant use of Proleukin with other products that cause neurotoxicity may result in a greater risk of severe neurotoxicity.

### 5.3 Serious Infections Including Sepsis

Proleukin can cause impaired neutrophil function (reduced chemotaxis) and an increased risk of disseminated infection, including sepsis and bacterial endocarditis. Treat pre-existing bacterial infections prior to initiating Proleukin. Consider antibiotic prophylaxis in patients with indwelling central lines. Monitor patients for the development of signs and symptoms of infection during treatment and withhold Proleukin based on severity [see *Dosage and Administration* (2.4)].

### 5.4 Renal Toxicity

Serious renal toxicity, including oliguria and renal failure can occur with Proleukin [see *Adverse Reactions* (6.1, 6.2)]. Pre-existing renal impairment or coadministration of Proleukin with other products known to cause renal toxicity may increase this risk. If possible, avoid concomitant use of Proleukin with other product(s) with a known potential to cause renal toxicity. Serum creatinine should be ≤1.5 mg/dL before beginning Proleukin. Monitor serum creatinine at baseline and daily throughout each course of therapy. Withhold Proleukin, or permanently discontinue, based on severity [see *Dosage and Administration* (2.4)].

### 5.5 Immune-mediated Adverse Reactions

Exacerbation of pre-existing autoimmune disease or initial presentation of autoimmune and inflammatory disorders has been reported following treatment with Proleukin. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. These have included exacerbation of Crohn's disease, colitis, scleroderma, thyroiditis, inflammatory arthritis, diabetes mellitus, oculo-bulbar myasthenia gravis, crescentic IgA glomerulonephritis, cholecystitis, cerebral vasculitis,

Stevens-Johnson syndrome, bullous pemphigoid, myocarditis, myositis, and neuritis including optic neuritis resulting in blindness [see *Adverse Reactions* (6.2)].

Proleukin may increase the risk of allograft rejection in transplant patients [see *Contraindications* (4)].

Hypothyroidism, sometimes preceded by hyperthyroidism, has been reported following Proleukin treatment. Evaluate thyroid function at baseline and periodically during treatment and initiate thyroid replacement therapy as clinically indicated.

Hyperglycemia and/or diabetes mellitus has been reported during Proleukin therapy. Monitor patients for hyperglycemia and initiate treatment with insulin as clinically indicated.

## **5.6 Embryo-Fetal Toxicity**

Based on findings in an animal study and its mechanism of action, Proleukin may cause fetal harm or loss of pregnancy when administered to a pregnant woman. In pregnant rats, aldesleukin has been shown to have embryo-lethal effects at doses 27 times and maternal toxicities at doses 2.1 times the human exposure at the recommended clinical dose. Advise pregnant women of the potential risk to a fetus. Advise female patients of reproductive potential to use effective contraception during treatment with Proleukin [see *Use in Specific Populations* (8.1, 8.3)].

## **5.7 Serious Manifestations of Eosinophilia**

Serious manifestations of eosinophilia involving eosinophilic infiltration of cardiac and pulmonary tissues can occur following Proleukin.

## **5.8 Delayed Adverse Reactions to Iodinated Contrast Media**

A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2-containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions. The onset of symptoms usually occurred within hours (most commonly 1 to 4 hours) following the administration of contrast media. These reactions include fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria. These reactions may resemble the immediate side effects caused by interleukin-2 administration. Most events were reported to occur when contrast media was given within 4 weeks after the last dose of interleukin-2. These events were also reported to occur when contrast media was given several months after interleukin-2 treatment [see *Adverse Reactions* (6.2)].

## **5.9 Severe Hypersensitivity Reactions**

Proleukin can cause severe hypersensitivity reactions, including anaphylactic reactions. Permanently discontinue Proleukin in patients who experience a severe hypersensitivity reaction [see *Contraindications* (4), *Adverse Reactions* (6.2)].

## **5.10 Infusion-Related Reactions**

Proleukin can cause fevers, chills, or rigors. Premedicate patients with an antipyretic prior to beginning Proleukin and continue during treatment as needed for fever [see *Adverse Reactions* (6.2) and *Dosage and Administration* (2.3)].

# **6 ADVERSE REACTIONS**

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Capillary Leak Syndrome [see *Warnings and Precautions* (5.1)].
- Neurotoxicity [see *Warnings and Precautions* (5.2)].
- Serious Infections Including Sepsis [see *Warnings and Precautions* (5.3)].
- Renal Toxicity [see *Warnings and Precautions* (5.4)].
- Immune-Mediated Adverse Reactions [see *Warnings and Precautions* (5.5)].
- Serious Manifestations of Eosinophilia [see *Warnings and Precautions* (5.7)].
- Severe Hypersensitivity Reactions [see *Warnings and Precautions* (5.9)].
- Infusion-Related Reactions [see *Warnings and Precautions* (5.10)].

## **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of Proleukin was evaluated in a series of single and multicenter, controlled studies enrolling a total of 525 patients with metastatic renal cell carcinoma (mRCC)

studies) or metastatic melanoma (metastatic melanoma studies) [see *Clinical Studies* (14.1, 14.2)].

In patients who received Proleukin in these studies, fatal adverse reactions occurred in 4% (11/255) of the patients with metastatic RCC, and 2% (6/270) of the patients with metastatic melanoma.

In these studies, >90% of patients had doses withheld for adverse reactions [see *Dosage and Administration* (2.4)].

The most common ( $\geq 30\%$ ) adverse reactions were hypotension, hyperbilirubinemia, dyspnea, rash, diarrhea, oliguria, chills, vomiting, thrombocytopenia, nausea, confusional state, and increased creatinine.

Table 4 summarizes adverse reactions that occurred in these studies.

**Table 4: Adverse Reactions ( $\geq 10\%$  all grades or  $\geq 1\%$  Grade 4) in Patients with Metastatic Renal Cell Carcinoma or Metastatic Melanoma (n=525) receiving Proleukin**

Adverse Reaction	Proleukin N = 525	
	All Grades (%)	Grade 4 (%)
<b>General disorders</b>		
Chills	52	0
Pyrexia	29	1
Edema peripheral	28	0
Malaise	27	0
Asthenia	23	0
Edema	15	0
Pain	12	0
<b>Cardiac disorders</b>		
Hypotension	71	3
Blood pressure fluctuation	Not documented	1
Tachycardia	23	0
Dilated veins	13	0
Supraventricular tachycardia	12	1
Ventricular tachycardia	<10	1
Cardiovascular disorder <sup>a</sup>	11	0
Myocardial infarction	<10	1
Arrhythmia	10	0
Cardiac arrest	<10	1
<b>Gastrointestinal disorders</b>		
Diarrhea	67	2
Vomiting	50	0
Nausea	35	0
Stomatitis	22	<1
Decreased appetite	20	0
Abdominal pain	11	0
Abdominal distention	10	0
<b>Blood and lymphatic system disorders</b>		
Thrombocytopenia	37	1
Anemia	29	0
Leukopenia	16	0
Disseminated intravascular coagulation	<10	1
<b>Infections</b>		
Infections	13	1
Sepsis	<10	1
<b>Hepatobiliary disorders</b>		
Hyperbilirubinemia	40	2
Aspartate aminotransferase increased	23	1
<b>Metabolic and nutritional disorders</b>		
Weight increased	16	0
Acidosis	12	1
Hypomagnesemia	12	0
Hypocalcemia	11	<1
Blood alkaline phosphatase increased	10	0
<b>Nervous system disorders</b>		
Confusional state	34	1

Stupor	<10	1
Coma	<10	2
Psychotic disorder	<10	1
Somnolence	22	0
Anxiety	12	0
Dizziness	11	0
<b>Respiratory, thoracic, and mediastinal disorders</b>		
Dyspnea	43	1
Lung disorder <sup>b</sup>	24	0
Respiratory disorder <sup>c</sup>	11	3
Apnea	<10	1
Cough	11	0
Rhinitis	10	0
<b>Skin and subcutaneous tissue disorders</b>		
Rash	42	0
Pruritis	24	0
Dermatitis exfoliative	18	0
<b>Renal and urinary disorders</b>		
Oliguria	63	6
Blood creatinine increased	33	1
Anuria	<10	5
Acute kidney injury	<10	1

<sup>a</sup> Cardiovascular disorder: Electrocardiogram abnormal, cardiac failure congestive.

<sup>b</sup> Lung disorder: Pulmonary congestion, rales, rhonchi.

<sup>c</sup> Respiratory disorder: Acute respiratory distress syndrome, lung infiltration, lung disorder, respiratory failure, endotracheal intubation.

Additional life-threatening adverse reactions (Grade 4) were reported by <1% of the 525 patients:

- Cardiac disorders: bradycardia, pericardial effusion, ventricular extrasystoles, myocardial ischemia, arrhythmia supraventricular, coronary artery disease, atrioventricular block second degree, endocarditis
- Eye disorders: mydriasis, pupillary disorder
- Gastrointestinal disorders: intestinal perforation, gastrointestinal hemorrhage, hematemesis, pancreatitis, diarrhea hemorrhagic
- General disorders and administration site conditions: hypothermia
- Infections and infestations: gangrene
- Metabolism and nutrition disorders: hyperuricemia
- Nervous system disorders: syncope, neuropathy peripheral, seizure, generalized tonic-clonic seizure
- Investigations: liver function tests abnormal, blood urea increased
- Psychiatric disorders: agitation, paranoia
- Renal and urinary disorders: renal failure, renal tubular necrosis
- Respiratory, thoracic and mediastinal disorders: respiratory acidosis, asthma, pulmonary edema, hyperventilation, hypoxia, hemoptysis, hypoventilation, pneumothorax
- Vascular disorders: shock, hemorrhage, phlebitis, thrombosis

#### Other Clinical Trial Experience

The following serious adverse reactions were reported in patients with RCC, melanoma, or other cancers treated with Proleukin-based regimens (n >1800 patients) using dosages other than the recommended dosage:

- Cardiovascular disorders: transient ischemic attacks, pericarditis
- Gastrointestinal disorders: duodenal ulcer; gastrointestinal necrosis, tracheo-esophageal fistula
- Nervous system disorders: meningitis, brain edema
- Renal and urinary disorders: nephritis (allergic)

In the same clinical population, the following fatal events each occurred with a frequency of <1%: hyperthermia malignant; cardiac arrest; myocardial infarction; pulmonary embolism; cerebrovascular accident; intestinal perforation; hepatic failure or renal failure; severe depression leading to suicide; pulmonary edema; respiratory arrest; respiratory failure. Patients with ECOG PS of 1 or higher had a higher treatment-related mortality and serious adverse events.

#### **6.2 Post Marketing Experience**

The following adverse reactions have been identified during post-approval use of Proleukin. Because these reactions are reported voluntarily from a population of

uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Blood and lymphatic system disorders: neutropenia, febrile neutropenia, eosinophilia, lymphopenia
- Cardiac disorders: cardiomyopathy, cardiac tamponade
- Endocrine disorders: hyperthyroidism
- Gastrointestinal disorders: gastritis, intestinal obstruction
- General disorders and administration site conditions: injection site necrosis
- Hepatobiliary disorders: hepatitis, hepatosplenomegaly, cholecystitis
- Immune system disorders: anaphylactic reaction, angioedema, urticaria
- Infections and infestations: pneumonia (bacterial, fungal, viral), endocarditis, cellulitis
- Metabolism and nutrition disorders: hyponatremia, hypophosphatemia
- Musculoskeletal and connective tissue disorders: myopathy, rhabdomyolysis
- Nervous system disorders: encephalopathy, extrapyramidal disorder, neuralgia
- Psychiatric disorders: insomnia
- Vascular disorders: hypertension, subdural hemorrhage, subarachnoid hemorrhage, cerebral hemorrhage, retroperitoneal hemorrhage

## 7 DRUG INTERACTIONS

Drug interaction studies with Proleukin have not been conducted. The drug interaction information described below have been observed post-marketing.

### 7.1 Effect of Other Drugs on Proleukin

#### Glucocorticoids

Avoid concomitant use of glucocorticoids. Coadministration with glucocorticoids may reduce aldesleukin antitumor effectiveness.

### 7.2 Effect of Proleukin on Other Drugs

#### Radiographic Iodinated Contrast Media

Monitor for delayed adverse reactions in patients receiving iodinated contrast media following Proleukin. Administration of radiographic iodinated contrast media following administration of interleukin-2 resulted in acute, atypical adverse reactions that resemble the immediate side effects caused by Proleukin in some patients [see *Warnings and Precautions* (5.8)].

#### Effect on Cytochrome P-450 Substrates

For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentration changes of such CYP substrates when co-administered with Proleukin.

Aldesleukin causes release of cytokines [see *Clinical Pharmacology* (12.2)] that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

Based on findings in an animal study and its mechanism of action, Proleukin may cause fetal harm or loss of pregnancy when administered to a pregnant woman [see *Clinical Pharmacology* (12.1)]. Data on the use of Proleukin in pregnant women are limited and insufficient to assess the drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes; however, development of capillary leak syndrome during pregnancy can lead to adverse fetal outcomes (see *Clinical Considerations*).

Intravenous administration of aldesleukin to pregnant rats during the period of organogenesis resulted in embryo lethality at doses 27 times and maternal toxicities at doses 2.1 times the human exposure at the recommended clinical dose (see *Data*). Advise pregnant women of the potential risk to a fetus.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%–4% and 15–20%, respectively.

#### Clinical Considerations

#### Fetal/Neonatal Adverse Reactions

Capillary leak syndrome in women who are exposed to Proleukin during pregnancy may result in maternal hypotension and decreased placental perfusion. Severe or prolonged

maternal hypotension and decreased placental perfusion can lead to intrauterine growth restriction, perinatal asphyxia, or fetal/neonatal demise. Monitor fetal and neonatal status in pregnant women who develop capillary leak syndrome associated with Proleukin.

#### Data

##### *Animal Data*

Aldesleukin has been shown to have embryolethal effects in rats when given in doses at 27 to 36 times the human dose (scaled by body weight). Significant maternal toxicities were observed in pregnant rats administered aldesleukin by IV injection at doses 2.1 to 36 times higher than the human dose during critical period of organogenesis.

## **8.2 Lactation**

##### Risk Summary

There are no data on the presence of aldesleukin in either human or animal milk, the effects on the breastfed child, or the effects on milk production. Maternal cytokines are known to be present in human breast milk. Because of the potential for serious adverse reactions from Proleukin in a breastfed child, such as impaired immune function, advise women not to breastfeed during treatment.

## **8.3 Females and Males of Reproductive Potential**

Based on animal data and mechanism of action, Proleukin may cause embryo-fetal harm [see *Use in Specific Populations* (8.1)].

##### Pregnancy Testing

Verify pregnancy status of females of reproductive potential prior to initiating Proleukin [see *Use in Specific Populations* (8.1)].

##### Contraception

##### *Females*

Advise females of reproductive potential to use effective contraception during treatment with Proleukin.

## **8.4 Pediatric Use**

The safety and effectiveness of Proleukin have not been established in pediatric patients.

## **8.5 Geriatric Use**

Clinical studies of Proleukin did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.

## **10 OVERDOSAGE**

Exceeding the recommended dose of Proleukin has been associated with a more rapid onset of severe or life-threatening toxicities. Treat toxicities supportively; life-threatening toxicities may be ameliorated by the intravenous administration of dexamethasone.

## **11 DESCRIPTION**

Aldesleukin is a human interleukin-2 lymphocyte growth factor produced by recombinant DNA technology using a genetically engineered *E. coli* strain containing an analog of the human interleukin-2 gene. It is a purified protein with a molecular weight of approximately 15,300 Da. This recombinant form differs from native interleukin-2 in the following ways: a) aldesleukin is not glycosylated; b) the molecule has no N-terminal alanine; c) the molecule has serine substituted for cysteine at amino acid position 125. Proleukin exists as biologically active, non-covalently bound microaggregates with an average size of 27 recombinant interleukin-2 molecules; the aggregation state of aldesleukin may differ compared to native interleukin-2.

The manufacturing process for aldesleukin involves fermentation in a defined medium containing tetracycline hydrochloride. The presence of tetracycline hydrochloride is not detectable in the final product.

Proleukin (aldesleukin) for injection is a sterile, preservative-free white to off-white, lyophilized powder, which has a cake-like appearance, supplied in single-dose vials for intravenous administration after reconstitution and dilution. When reconstituted with 1.2 mL Sterile Water for Injection, USP, each mL contains 18 million International Units (1.1 mg) aldesleukin, mannitol (50 mg), sodium dodecyl sulfate (0.19 mg), buffered with disodium hydrogen phosphate dihydrate (1.12 mg) and sodium dihydrogen phosphate

dihydrate (0.19 mg) to a pH of 7.5 (range 7.2 to 7.8).

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

Aldesleukin is an interleukin-2 lymphocyte growth factor. The antitumor activity of aldesleukin has not been fully characterized. In vitro studies performed on human cell lines show enhancement of lymphocyte mitogenesis and cytotoxicity, induction of killer cell activity [lymphokine-activated killer (LAK) and natural killer (NK) cells] and interferon gamma production, and proliferation of human interleukin-2-dependent cell lines.

Administration of aldesleukin in animals and humans produces multiple immunological effects in a dose-dependent manner. These effects include activation of cellular immunity and the production of cytokines including tumor necrosis factor, IL-1, and interferon gamma. In vivo experiments in murine melanoma and sarcoma tumor models have shown inhibition of tumor growth.

### **12.2 Pharmacodynamics**

Dose-dependent immunological effects including activation of cellular immunity with lymphocytosis, eosinophilia, and thrombocytopenia, and the production of cytokines including tumor necrosis factor, IL-1, and gamma interferon were observed following administration of aldesleukin in animals and humans.

Aldesleukin exposure-response relationships and the time course of pharmacodynamic response are unknown.

### **12.3 Pharmacokinetics**

Aldesleukin serum concentrations change proportionally with the Proleukin dosage.

#### **Distribution**

Aldesleukin is rapidly distributed (distribution half-life of 13 minutes) into the extravascular space following a Proleukin intravenous infusion.

#### **Elimination**

The serum elimination half-life aldesleukin is 85 minutes in patients with cancer following a 5-minute intravenous infusion of Proleukin. The mean clearance rate of aldesleukin is 268 mL/min.

#### **Metabolism**

Aldesleukin is metabolized to amino acids in the proximal convoluted tubules of the kidney.

#### **Excretion**

Aldesleukin is primarily excreted in the kidney by both glomerular filtration and peritubular extraction. In the kidney it is metabolized and excreted into urine with little or no aldesleukin present.

### **12.6 Immunogenicity**

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies.

In clinical studies, using an enzyme-linked immunosorbent assay (ELISA), low titers of anti-aldesleukin antibodies were observed in 74% (57 of 77) of patients with metastatic renal cell carcinoma treated with an every 8-hour Proleukin regimen and in 66% (33 of 50) of patients with metastatic melanoma treated with a variety of intravenous regimens. In a separate study in 13 patients, following the first cycle of therapy, the geometric mean aldesleukin exposure (AUC) on Day 15 compared to Day 1 increased by 68% in 11 patients who developed anti-aldesleukin antibodies while no change was observed in the 2 antibody-negative patients. Overall, neutralizing antibodies were detected in 1 patient. Based on these data, the clinical relevance of anti-aldesleukin antibodies could not be assessed.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

The carcinogenic and genotoxic potential of aldesleukin have not been evaluated.

Animal fertility studies have not been conducted with aldesleukin.

## 13.2 Animal Toxicology and/or Pharmacology

Repeated doses of aldesleukin administered to animals intravenously resulted in dose-dependent extramedullary hematopoiesis and lymphoid hyperplasia.

## 14 CLINICAL STUDIES

### 14.1 Metastatic Renal Cell Cancer

The efficacy of Proleukin was evaluated in two hundred fifty-five patients with metastatic renal cell carcinoma (mRCC) in 7 clinical studies conducted at 21 institutions (mRCC studies). Eligible patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 and normal organ function as determined by cardiac stress test, pulmonary function tests, and creatinine  $\leq 1.5$  mg/dL. Studies excluded patients with brain metastases, active infections, organ allografts, and diseases requiring steroid treatment. Not all patients in these studies received the recommended Proleukin dosing regimen.

The major efficacy outcome measure was objective response rate (ORR) determined by investigator assessment per ECOG response criteria for solid tumors (1982).

Efficacy results are summarized in Table 5.

**Table 5: Proleukin Efficacy Results in mRCC Studies**

	<b>Proleukin (n=255)</b>
<b>Objective Response Rate</b>	
ORR (95% CI), %	15% (11, 20)
Complete Response (CR), %	7%
Partial Response (PR), %	8%
<b>Duration of response (months)</b>	
Number of Patients Who Responded	n= 37
Median (months)	54
Range (months)	3, 131+ + Denotes ongoing responses

### 14.2 Metastatic Melanoma

The efficacy of Proleukin was evaluated in two hundred seventy patients with metastatic melanoma in 8 clinical studies conducted at 22 institutions (metastatic melanoma studies). Eligible patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1 and normal organ function as determined by cardiac stress test, pulmonary function tests, and creatinine  $\leq 1.5$  mg/dL. Studies excluded patients with brain metastases, active infections, organ allografts, and diseases requiring steroid treatment. Not all patients in these studies received the recommended Proleukin dosing regimen.

Patients with metastatic melanoma received a median of 18 of the 28 scheduled doses of Proleukin during the first course of therapy.

The major efficacy outcome measure was objective response rate (ORR) determined by investigator assessment per ECOG response criteria for solid tumors (1982).

Efficacy results are summarized in Table 6.

**Table 6: Proleukin Efficacy Results in Metastatic Melanoma Studies**

	<b>Proleukin (n=270)</b>
<b>Objective Response Rate</b>	
ORR (95% CI)	16% (12, 21)
Complete Response (CR), %	6%
Partial Response (PR), %	10%
<b>Duration of response (months)</b>	
Number of Patients Who Responded	n= 43
Median (months) (95% CI)	9
Range (months)	1, 122+

+ Denotes ongoing responses

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

Proleukin® (aldesleukin) for injection is supplied in single-dose vials. Each vial contains 22 million International Units (1.3 mg) of Proleukin.

NDC 76310-022-01      Individually boxed single-dose vial

Store unopened vials refrigerated at 2° to 8°C (36° to 46°F) in the original carton to protect from light.

Do not use beyond the expiration date printed on the vial. **NOTE:** This product contains no preservative.

## **17 PATIENT COUNSELING INFORMATION**

Inform patients or caregivers of the following risks of Proleukin:

### Capillary Leak Syndrome

Advise patients about the risk of capillary leak syndrome and to inform their healthcare provider immediately if they develop new or worsening symptoms of hypotension, dyspnea, or edema [see *Warnings and Precautions (5.1)*].

### Neurotoxicity

Advise the patient to inform their healthcare provider immediately if they develop mental status changes, speech difficulties, blindness, ataxia, hallucinations, agitation, or experienced a seizure [see *Warnings and Precautions (5.2)*].

### Serious Infections Including Sepsis

Advise patients to inform their healthcare provider immediately if they develop signs of infection or sepsis including fever, chills, weakness, dyspnea [see *Warnings and Precautions (5.3)*].

### Immune-mediated Adverse Reactions

Advise patients that Proleukin can cause immune-mediated adverse reactions and can exacerbate pre-existing autoimmune disease. These immune-mediated adverse reactions can occur in any organ system or tissue. Proleukin may also increase the risk of allograft rejection in transplant patients. Advise patients to contact their healthcare provider for any new or worsening signs or symptoms [see *Warnings and Precautions (5.5)*].

Hypothyroidism, sometimes preceded by hyperthyroidism, has been reported following Proleukin treatment. Evaluate thyroid function at baseline and periodically during treatment and initiate thyroid replacement therapy as clinically indicated.

Hyperglycemia and/or diabetes mellitus has been reported during Proleukin therapy. Monitor patients for hyperglycemia and initiate treatment with insulin as clinically indicated.

### Serious Manifestations of Eosinophilia

Advise patients to inform their healthcare provider immediately if they develop serious symptoms of eosinophilia including new severe rash or dyspnea [see *Warnings and Precautions (5.7)*].

### Delayed Adverse Reactions to Iodinated Contrast Media

Advise patients to inform their health care provider that they received Proleukin prior to undergoing imaging that requires iodinated contrast material [see *Warnings and Precautions (5.8)*].

### Embryo-Fetal Toxicity

Advise females of reproductive potential to use effective contraception during treatment with Proleukin [see *Warnings and Precautions (5.6)*, *Use in Specific Populations (8.1, 8.3)*].

Proleukin may cause fetal harm. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions (5.6)*, *Use in Specific Populations (8.1, 8.3)*].

### Lactation

Advise females not to breastfeed during treatment with Proleukin [see *Use in Specific Populations (8.2)*].

### Hypersensitivity

Advise patients to inform their healthcare provider if they develop signs and symptoms of hypersensitivity reactions [see *Warnings and Precautions (5.9)*].

Manufactured by:  
Clinigen, Inc.  
Malvern, PA 19355  
U.S. License No. 2154

At

Boehringer Ingelheim Pharma  
Biberach/Riss, Germany



For additional information, contact Clinigen, Inc. 1-877-PROLEUKIN (1-877-776-5385)  
PROLEUKIN is a registered trademark.

© Clinigen, Inc.



#### Principal Display Panel - Proleukin Label

NDC 76310-022-01 Rx only


**Proleukin®**  
**(aldesleukin)**

for injection

22 million International Units/Vial  
(1.3 mg/vial)

Single-Dose Vial • Discard Unused Portion

**CLINIGEN** PR019VL-03



#### Principal Display Panel - Proleukin Carton

NDC 76310-022-01


**Proleukin®**  
**(aldesleukin)**

for injection

22 million  
International Units/Vial  
(1.3 mg/vial)

Single-Dose Vial Discard Unused Portion  
For Intravenous Infusion After Dilution  
Refrigerate    **Rx only**

**CLINIGEN**



## PROLEUKIN

aldesleukin injection, powder, lyophilized, for solution

### Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:76310-022
Route of Administration	INTRAVENOUS		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
aldesleukin (UNII: M89N0Q7EQR) (aldesleukin - UNII:M89N0Q7EQR)	aldesleukin	1.1 mg in 1 mL

### Inactive Ingredients

Ingredient Name	Strength
MANNITOL (UNII: 30WL53L36A)	
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JH2SW)	
SODIUM LAURYL SULFATE (UNII: 368GB5141)	
SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM (UNII: GR686LBA74)	
WATER (UNII: 059QF0KOOR)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:76310-022-01	1 in 1 CARTON	12/31/2019	01/19/2026
1		1 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA103293	05/05/1992	01/19/2026

**Labeler** - Clinigen Limited (211471076)

Revised: 6/2024

Clinigen Limited